V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220009503 | 220012077 | 0 | 59.9 | Curative (C) | 2017-06-03 | 2017-06-16 | Alemtuzumab cond (RI ALLO CAMP100) | 02 | N | 220006368 | MITOXANTRONE |
| 220009504 | 220012077 | 1.67 | 73.999 | null | null | 2016-05-21 | Cisplatin | null | null | 220006368 | UKALL XII |
| 220009505 | 220012077 | 1.82 | 72.85 | Curative (C) | 2019-01-08 | 2019-01-08 | Cisplatin + Pemetrexed | 2 | Y | 220006368 | PACLITAXEL |
| 220009506 | 220012077 | 1.63 | 61.1 | Palliative (P) | 2017-10-16 | 2017-10-16 | IDARUBICIN | N | N | 220006368 | MERCAPTOPURINE |
| 220009507 | 220012077 | 1.58 | 51.9 | Curative (C) | 2018-06-17 | 2018-06-24 | IDARUBICIN + MITOXANTRONE + Tretinoin | N | N | 220006368 | ATG + BUSULFAN + FLUDARABINE |
| 220009508 | 220003870 | null | null | Curative (C) | null | 2015-06-12 | Pentostatin | null | null | 220008837 | METHOTREXATE INTRATHECAL |
| 220009509 | 220003871 | 1.67 | 68.8 | null | 2016-01-13 | 2016-01-13 | ALL UKALL2011 Maintenance B4 | 02 | N | 220008953 | RUXOLITINIB |
| 220009510 | 220003872 | 1.63 | 82.9 | Curative (C) | 2013-08-07 | 2013-08-09 | CISPLATIN + ETOPOSIDE | 2 | null | 220009544 | BOSUTINIB |
| 220009511 | 220003873 | 1.77 | 16.8 | Curative (C) | 2014-06-27 | 2014-06-28 | TOPARP TRIAL | 02 | N | 220010013 | BOSUTINIB |
| 220009512 | 220012078 | null | 68.05 | Disease modification (D) | 2017-10-11 | 2017-10-31 | Capecitabine | N | null | 220010069 | CYTARABINE INTRATHECAL |
| 220009513 | 220012078 | 1.8 | 64.5 | Disease modification (D) | null | 2018-02-14 | Doxorubicin 75mg/m2 | N | Y | 220010069 | DABRAFENIB + TRAMETINIB |
| 220009514 | 220003874 | 1.55 | 0 | Disease modification (D) | 2017-07-17 | 2017-07-17 | OCTREOTIDE | 02 | N | 220010837 | BOSUTINIB |
| 220009515 | 220003875 | 1.94 | null | Curative (C) | 2015-03-18 | 2015-03-18 | BEP 3 day | 02 | N | 220011016 | TRIPLE INTRATHECAL |
| 220009516 | 220003876 | 1.8 | 0 | Curative (C) | null | 2015-12-30 | Cisplatin + Pemetrexed | N | N | 220012398 | FLUDARABINE + MELPHALAN |
| 220009517 | 220003877 | null | null | Curative (C) | 2015-12-21 | 2015-12-28 | Triple / Double Intrathecal Therapy | N | N | 220012731 | TRIPLE INTRATHECAL |
| 220009518 | 220003877 | 1.77 | 68 | Curative (C) | 2017-12-01 | 2017-12-02 | Alemtuzumab+Busulfan+CyclophosphMUD | 02 | N | 220012731 | FLUDARABINE + MELPHALAN |
| 220009519 | 220003877 | 0 | null | Palliative (P) | 2017-05-29 | 2017-12-12 | CHOP R - 21 days | N | N | 220012731 | LENALIDOMIDE |
| 220009520 | 220003877 | null | 46.7 | null | 2014-08-22 | 2014-08-25 | Fludarabine + Melphalan RIC Allo | N | N | 220012731 | FLUOROURACIL |
| 220009521 | 220003878 | 1.57 | 0 | Curative (C) | 2016-06-13 | 2016-06-14 | DABRAFENIB + TRAMETINIB | 01 | N | 220013190 | TRIPLE INTRATHECAL |
| 220009522 | 220003879 | 1.5 | 72.1 | Palliative (P) | 2015-11-10 | 2015-11-11 | Cisplatin + Pemetrexed | 02 | N | 220013384 | IRINOTECAN + MDG |
| 220009523 | 220012080 | 0 | 58.6 | Curative (C) | null | 2018-06-27 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | null | null | 220014128 | FLUDARABINE + MELPHALAN |
| 220009524 | 220012080 | 1.63 | 85.5 | Radical (R) | 2015-04-17 | 2015-04-17 | Cyclophosphamide TBI Allograft | N | null | 220014128 | LANREOTIDE |
| 220009525 | 220003880 | 0 | 8.7 | Curative (C) | 2016-03-26 | 2016-04-02 | Sorafenib | 02 | N | 220014290 | CYTARABINE + MITOXANTRONE |
| 220009526 | 220012081 | 1.84 | 94.8 | Palliative (P) | 2014-09-30 | 2014-09-30 | Vemurafenib | 02 | N | 220014509 | BUSULPHAN |
| 220009527 | 220003881 | null | 170 | null | null | 2014-12-09 | Mitox + Tretinoin Spanish Course 3 | 2 | N | 220014919 | CISPLATIN + PEMETREXED |
| 220009528 | 220003881 | 1.7 | 59.9 | Curative (C) | 2018-08-31 | 2018-08-31 | Cytarabine intrathecal | 2 | null | 220014919 | FBC |
| 220009529 | 220003881 | 1.68 | 0 | Curative (C) | 2018-03-29 | 2018-03-29 | CYCLOPHOSPHAMIDE + FLUDARABINE | 2 | N | 220014919 | MITOXANTRONE |
| 220009530 | 220003881 | 1.66 | 0 | Curative (C) | 2016-03-25 | 2016-05-02 | FEC + DOCETAXEL | N | N | 220014919 | IDARUBICIN + MITOXANTRONE + TRETINOIN |
| 220009531 | 220003881 | 1.78 | 63.2 | Disease modification (D) | 2018-10-04 | 2018-10-04 | NHL 2003 Gp B COP | N | N | 220014919 | BUSULPHAN |
| 220009532 | 220003882 | 1.75 | null | Adjuvant (A) | 2016-08-18 | 2016-08-28 | ALL UKALL2011 Maintenance B4 | N | N | 220016351 | CHLORAMBUCIL + OFATUMUMAB |
| 220009533 | 220003883 | null | 97.5 | Adjuvant (A) | 2018-01-16 | 2018-01-16 | ECF | N | Y | 220016525 | BEVACIZUMAB |
| 220009534 | 220003884 | null | 121 | Curative (C) | 2017-04-05 | 2017-04-05 | MITOXANTRONE + TRETINOIN | N | N | 220016581 | FLUDARABINE + MELPHALAN |
| 220009535 | 220003885 | 1.68 | 0 | Curative (C) | null | 2016-10-03 | DAUNORUBICIN | N | N | 220016621 | IDARUBICIN |
| 220009536 | 220003885 | null | null | null | null | 2013-07-30 | Paclitaxel 7 day | null | null | 220016621 | CHLORAMBUCIL + OBINUTUZUMAB |
| 220009537 | 220003886 | 1.79 | null | Curative (C) | 2015-04-06 | 2015-04-21 | IPILIMUMAB + NIVOLUMAB | 02 | N | 220016746 | CYTARABINE + FLUDARABINE + IDARUBICIN |
| 220009538 | 220003887 | 1.74 | null | null | 2016-05-24 | 2016-05-24 | Fludarabine + Melphalan RIC Allo | N | N | 220017143 | UKALL XII |
| 220009539 | 220003888 | 1.73 | 57 | Curative (C) | 2016-11-20 | 2016-11-30 | CISPLATIN + ETOPOSIDE | 02 | N | 220017507 | FLUDARABINE + MELPHALAN |
| 220009540 | 220003889 | 1.74 | 70.8 | Curative (C) | 2014-11-15 | 2014-11-15 | Busulfan Oral | 02 | N | 220017610 | ARSENIC TRIOXIDE + TRETINOIN |
| 220009541 | 220003890 | 1.71 | 100 | null | null | 2013-06-26 | Arsenic Trioxide (consolidation) | null | null | 220017673 | METHOTREXATE INTRATHECAL |
| 220009542 | 220003891 | 1.75 | 94.1 | Palliative (P) | 2015-05-14 | 2015-05-14 | DABRAFENIB + TRAMETINIB | 2 | N | 220018110 | DACARBAZINE |
| 220009543 | 220003891 | 1.55 | 73.95 | Curative (C) | 2016-02-09 | 2016-04-03 | CVP R | 2 | N | 220018110 | FLA |
| 220009544 | 220003891 | 1.76 | 135.3 | Palliative (P) | 2015-11-18 | 2015-11-25 | Arsenic Triox + Tretinoin Ind W1-4 | N | N | 220018110 | DABRAFENIB + TRAMETINIB |
| 220009545 | 220003892 | 1.78 | 88.6 | Curative (C) | 2015-01-02 | 2015-01-03 | Triple / Double Intrathecal Therapy | N | N | 220018693 | CARBOPLATIN + RT |
| 220009546 | 220012085 | 1.8 | 103.4 | Disease modification (D) | 2017-08-04 | 2017-08-18 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | 2 | N | 220018755 | CABOZANTINIB |
| 220009547 | 220003893 | null | 95 | Curative (C) | 2017-08-09 | 2017-08-10 | IBRUTINIB | 02 | N | 220018780 | FBC |
| 220009548 | 220003893 | 1.66 | 56.6 | Palliative (P) | 2018-08-26 | 2018-08-26 | CISPLATIN + ETOPOSIDE | 2 | N | 220018780 | LI-1 TRIAL |
| 220009549 | 220003894 | 1.76 | 79.6 | Palliative (P) | null | 2017-11-28 | CISPLATIN + ETOPOSIDE | N | N | 220019061 | CARBO + FLUOROURACIL |
| 220009550 | 220003895 | 1.64 | 67.9 | Not known (9) | 2017-12-02 | 2017-12-02 | FEC + DOCETAXEL | 2 | N | 220019679 | CHOP |
| 220009551 | 220003896 | 1.58 | 88.8 | Curative (C) | 2016-09-02 | 2016-09-10 | ALL UKALL2011 IndB Std Dex (PegAsp) | 2 | N | 220020055 | ARSENIC TRIOXIDE + ATRA |
| 220009552 | 220003897 | 1.68 | null | null | 2017-12-20 | 2017-12-20 | Arsenic trioxide + Tretinoin | N | N | 220020101 | FLUDARABINE |